insulin glargine (Lantus)

Following an abbreviated submission:

insulin glargine (Lantus) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.

SMC restriction: patients in whom treatment with an insulin analogue is appropriate.

Its use should be targeted on patients with Type I diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin.

In patients with type 2 diabetes it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections.

The pre-filled pen has previously been accepted for restricted use in patients from the age of 6 years and above.